Trial Profile

A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase III Clinical Study to Assess Efficacy of PMZ-1620 Along With Standard Treatment in Patients of Acute Ischemic Stroke

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Sep 2023 According to a Pharmazz media release, company announced that it has entered into a license agreement with Sun Pharmaceutical Industries Limited to commercialise Tyvalz (Sovateltide) in India.
10 Feb 2023 Primary endpoint (Proportion of patients with change in NIHSS score (more than and equal to 6), mRS score (more than and equal to 2) from baseline) has been met as per results published in International Stroke Conference 2023.
10 Feb 2023 Primary (Proportion of patients with change in BI score (more than and equal to 40) from baseline) endpoint has not been met as per results published in International Stroke Conference 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com